Prism Medico & Pharmacy Intrinsic Value
Prism Medico & Pharmacy (PRISMMEDI) median intrinsic value is ₹17.10 from 6 valuation models (range ₹8–₹47), vs current price ₹27.86 — -38.6% downside (Trading Above Calculated Value), margin of safety -62.9%. Analyse PRISMMEDI shareholding pattern to track promoter, FII and institutional holdings.
PRISMMEDI Valuation Methods Summary — DCF, Graham Number & P/E
Prism Medico & Pharmacy intrinsic value across 6 models vs current price ₹27.86 — upside/downside and value range per method. Read PRISMMEDI ex-dividend dates for the complete payout history and dividend yield track record.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹8.36 | ₹6.69 - ₹10.03 | -70.0% | EPS: ₹0.60, Sector P/E: 12x |
| Book Value Method | asset | ₹17.33 | ₹15.60 - ₹19.06 | -37.8% | Book Value/Share: ₹21.67, P/B: 0.8x |
| Revenue Multiple Method | revenue | ₹46.67 | ₹42.00 - ₹51.34 | +67.5% | Revenue/Share: ₹46.67, P/S: 1.0x |
| PEG Ratio Method | growth | ₹8.36 | ₹7.52 - ₹9.20 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹8.36 | ₹7.52 - ₹9.20 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| Graham Defensive Method | conservative | ₹17.10 | ₹15.39 - ₹18.81 | -38.6% | EPS: ₹0.60, BVPS: ₹21.67 |
PRISMMEDI Intrinsic Value vs Market Price — All Valuation Models
Prism Medico & Pharmacy fair value range ₹8–₹47 vs current market price ₹27.86 across 6 valuation models. For current market price and key ratios, visit Prism Medico & Pharmacy screener.
PRISMMEDI Intrinsic Value Analysis — Undervalued or Overvalued?
Prism Medico & Pharmacy median intrinsic value ₹17.10, current price ₹27.86 — Trading Above Calculated Value by 38.6%, margin of safety -62.9%.
What is the intrinsic value of PRISMMEDI?
Based on our comprehensive analysis using 6 different valuation methods, the estimated intrinsic value of Prism Medico & Pharmacy (PRISMMEDI) is ₹17.10 (median value). With the current market price of ₹27.86, this represents a -38.6% variance from our estimated fair value.
The valuation range spans from ₹8.36 to ₹46.67, indicating ₹8.36 - ₹46.67.
Is PRISMMEDI undervalued or overvalued?
Based on our multi-method analysis, Prism Medico & Pharmacy (PRISMMEDI) appears to be trading above calculated value by approximately 38.6%.
PRISMMEDI Financial Health — Key Ratios vs Industry Benchmarks
Prism Medico & Pharmacy financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Operating Margin | 3.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.33x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
PRISMMEDI Cash Flow Quality — Operating & Free Cash Flow
Prism Medico & Pharmacy operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2019 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2018 | ₹4 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2017 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |